Objectives Existing scores are not accurate at predicting mortality in upper (UGIB) and lower (LGIB) gastrointestinal bleeding. We aimed to develop and validate a new pre-endoscopy score for predicting mortality in both UGIB and LGIB.
Design and setting International cohort study. Patients presenting to hospital with UGIB at six international centres were used to develop a risk score for predicting mortality using regression analyses. The score’s performance in UGIB and LGIB was externally validated and compared with existing scores using four international datasets. We calculated areas under receiver operating characteristics curves (AUROCs), sensitivities, specificities and outcome among patients classified as low risk and high risk.
Participants and results We included 3012 UGIB patients in the development cohort, and 4019 UGIB and 2336 LGIB patients in the validation cohorts. Age, Blood tests and Comorbidities (ABC) score was closer associated with mortality in UGIB and LGIB (AUROCs: 0.81–84) than existing scores (AUROCs: 0.65–0.75; p≤0.02). In UGIB, patients with low ABC score (≤3), medium ABC score (4–7) and high ABC score (≥8) had 30-day mortality rates of 1.0%, 7.0% and 25%, respectively. Patients classified low risk using ABC score had lower mortality than those classified low risk with AIMS65 (threshold ≤1) (1.0 vs 4.5%; p<0.001). In LGIB, patients with low, medium and high ABC scores had in-hospital mortality rates of 0.6%, 6.3% and 18%, respectively.
Conclusions In contrast to previous scores, ABC score has good performance for predicting mortality in both UGIB and LGIB, allowing early identification and targeted management of patients at high or low risk of death.
- gastrointestinal bleeding
Data availability statement
Data are available on reasonable request. Relevant anonymised patient-level data are available from the corresponding author SBL. Consent was not obtained but the presented data are anonymised and risk of identification is low.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Twitter @LGIBaudit, @iangralnek
Contributors The study was designed by SBL and AS. VB collected data. SBL and AS wrote the paper with considerable input from KO, LL, IG, VJ, IAM, JN, ER-C, RM, HRD and MS. All coauthors approved the final manuscript. SBL is the study guarantor.
Funding This study was sponsored by NHS Greater Glasgow and Clyde Health Board, Scotland, UK. Data collection in Glasgow, Singapore, and Dunedin was funded by a health board endowment, hospital research, and guthealthnetwork grant, respectively. The Italian validation cohort was sponsored by the three Italian scientific societies: AIGO, SIED, and SIGE. KO was supported by funding from NHS Blood and Transplant, Bowel Disease Research Foundation and a Research Fellowship from the Royal College of Surgeons of England.
Disclaimer The funders had no input to the study design, data collection, or interpretation, writing of report, or submission for publication.
Competing interests IG is a consultant, has a financial interest and is a member of the Medical Advisory Board of MOTUS GI. IG is a consultant for Boston Scientific, Symbionix and GI View. KO has received editorial fees for reviews on the same topic.
Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.
Provenance and peer review Not commissioned; externally peer reviewed.